Department of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Department of Urology, Skåne University Hospital, Malmö, Sweden.
Proteomics Clin Appl. 2021 May;15(2-3):e2000025. doi: 10.1002/prca.202000025. Epub 2021 May 4.
Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.
A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
提高前列腺癌（PC）的早期诊断和侵袭性判断对于选择合适的治疗方案和减少过度治疗非常重要。传统的标志物是血液中的总前列腺特异性抗原（PSA）水平，但缺乏特异性和准确区分惰性与侵袭性疾病的能力。
在这项研究中，我们试图确定与转移性 PC 相关的血清生物标志物特征。我们使用重组抗体微阵列测量了 363 份来自健康受试者、非转移性 PC 患者和转移性 PC 患者的血清样本中的 157 种分析物。
确定了一个由 69 种蛋白质组成的特征，可将转移性 PC 患者与健康对照区分开来。
在为转移性 PC 的检测提供新的前景之前，该生物标志物特征的临床价值需要在更大的独立患者队列中进行验证。
